Episode 82: Metastatic triple-negative breast cancer (TNBC)

Written By Inquisitive Oncology

Oncology for the Inquisitive Mind would like to issue a formal mae culpa to our listeners. You have joined us for over 12 months and over 80 episodes and listened to our ramblings and bad jokes. And it has taken 80 episodes for us to realise we have neglected the crucial and exciting subject of metastatic triple-negative breast cancer (TNBC). But fear not! We will rectify this egregious oversight with immediate effect. TNBC remains the scourge of the usually more optimistic breast cancer space. However, the fight of the world's oncologists continues across all fronts, and TNBC is no different. In today's episode, Michael and Josh will discuss the twin pillars of modern anti-cancer therapies: antibody-drug conjugates (sacituzumab govitecan) and immunotherapy (pembrolizumab). As so often the case, this is a growth area of medical oncology and one that we are very excited to (finally) address.

Links to studies discussed in this episode (subscription may be required):

  • ASCENT: https://www.nejm.org/doi/full/10.1056/NEJMoa2028485

  • KEYNOTE-355: https://www.nejm.org/doi/full/10.1056/NEJMoa2202809

Inquisitive Oncology
Previous

Oncosnacks 12: Enfortumab Vedotin skin toxicity management
Next

Fireside Chats 2. Time Toxicity in Early Phase Trials